Publications
2 shownA randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 1,622
- Institution
- University of Arizona Cancer Center
External Links
Identifiers
- ORCID
- 0000-0002-7789-5442
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.